
Vimta Labs (VIMTALABS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
975.6M
Gross Profit
787.6M
80.72%
Operating Income
238.3M
24.42%
Net Income
188.9M
19.37%
EPS (Diluted)
₹4.21
Balance Sheet Metrics
Total Assets
4.7B
Total Liabilities
876.8M
Shareholders Equity
3.8B
Debt to Equity
0.23
Cash Flow Metrics
Revenue & Profitability Trend
Vimta Labs Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 3.4B | 3.2B | 3.2B | 2.8B | 2.1B |
Cost of Goods Sold | 714.5M | 762.8M | 738.5M | 792.0M | 611.1M |
Gross Profit | 2.7B | 2.4B | 2.4B | 2.0B | 1.5B |
Gross Margin % | 79.2% | 76.0% | 76.6% | 71.3% | 70.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 92.3M | 109.8M | 115.2M | 89.0M | 79.2M |
Other Operating Expenses | 391.4M | 380.9M | 387.0M | 252.0M | 196.0M |
Total Operating Expenses | 483.7M | 490.7M | 502.2M | 341.0M | 275.2M |
Operating Income | 906.0M | 575.1M | 696.8M | 633.7M | 360.2M |
Operating Margin % | 26.3% | 18.1% | 22.1% | 23.0% | 17.3% |
Non-Operating Items | |||||
Interest Income | 15.7M | 13.4M | 12.0M | 8.3M | 4.1M |
Interest Expense | 13.9M | 15.2M | 9.3M | 8.3M | 17.3M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 890.0M | 544.8M | 650.0M | 556.8M | 285.4M |
Income Tax | 222.4M | 134.7M | 168.2M | 143.6M | 71.4M |
Effective Tax Rate % | 25.0% | 24.7% | 25.9% | 25.8% | 25.0% |
Net Income | 673.4M | 410.1M | 481.7M | 413.3M | 214.0M |
Net Margin % | 19.6% | 12.9% | 15.3% | 15.0% | 10.3% |
Key Metrics | |||||
EBITDA | 1.3B | 935.3M | 1.0B | 866.7M | 586.6M |
EPS (Basic) | ₹15.14 | ₹18.51 | ₹21.77 | ₹18.70 | ₹9.68 |
EPS (Diluted) | ₹14.93 | ₹18.24 | ₹21.35 | ₹18.32 | ₹9.68 |
Basic Shares Outstanding | 44469024 | 22150331 | 22128989 | 22107810 | 22107810 |
Diluted Shares Outstanding | 44469024 | 22150331 | 22128989 | 22107810 | 22107810 |
Income Statement Trend
Vimta Labs Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 158.4M | 134.4M | 305.0M | 108.0M | 61.9M |
Short-term Investments | 168.8M | 121.6M | 90.7M | 4.1M | 3.9M |
Accounts Receivable | 1.1B | 870.0M | 799.9M | 769.2M | 734.6M |
Inventory | 250.6M | 246.9M | 226.2M | 173.8M | 146.4M |
Other Current Assets | 100.8M | 100.8M | 100.8M | 83.7M | 75.5M |
Total Current Assets | 1.9B | 1.6B | 1.6B | 1.2B | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 89.4M | 32.3M | 32.3M | 32.3M | 32.3M |
Goodwill | 64.2M | 202.5M | 233.6M | 245.2M | 111.6M |
Intangible Assets | 64.2M | 90.9M | 122.0M | 133.6M | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 20.5M | 21.8M | 41.8M | 92.5M | 20.0K |
Total Non-Current Assets | 2.8B | 2.4B | 2.0B | 1.8B | 1.6B |
Total Assets | 4.7B | 4.0B | 3.6B | 3.1B | 2.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 104.9M | 82.3M | 144.4M | 123.4M | 148.3M |
Short-term Debt | 52.9M | 101.2M | 51.0M | 66.8M | 161.8M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 15.0M | 8.4M | 8.5M | 8.5M | 3.4M |
Total Current Liabilities | 643.7M | 540.7M | 572.8M | 477.5M | 539.1M |
Non-Current Liabilities | |||||
Long-term Debt | 32.2M | 90.7M | 98.9M | 126.6M | 142.4M |
Deferred Tax Liabilities | 0 | 780.0K | 690.0K | 740.0K | 700.0K |
Other Non-Current Liabilities | 82.2M | 53.3M | 45.2M | 55.8M | 38.4M |
Total Non-Current Liabilities | 233.2M | 262.8M | 232.6M | 254.6M | 260.6M |
Total Liabilities | 876.8M | 803.5M | 805.4M | 732.1M | 799.8M |
Equity | |||||
Common Stock | 44.5M | 44.3M | 44.3M | 44.2M | 44.2M |
Retained Earnings | 2.8B | 2.2B | 1.9B | 1.4B | 1.1B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.8B | 3.2B | 2.8B | 2.3B | 1.9B |
Key Metrics | |||||
Total Debt | 85.2M | 191.9M | 149.9M | 193.4M | 304.2M |
Working Capital | 1.2B | 1.0B | 1.1B | 766.1M | 566.2M |
Balance Sheet Composition
Vimta Labs Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 904.0M | 544.8M | 650.0M | 556.8M | 285.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 18.5M | 15.5M | 40.7M | 29.0M | - |
Working Capital Changes | -95.9M | -114.0M | -76.0M | -79.3M | -184.1M |
Operating Cash Flow | 812.6M | 430.7M | 616.4M | 503.4M | 110.7M |
Investing Activities | |||||
Capital Expenditures | -761.9M | -742.4M | -475.8M | -297.4M | -328.9M |
Acquisitions | 50.3M | - | - | - | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -716.8M | -742.4M | -475.8M | -297.4M | -328.9M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -44.3M | -44.3M | -44.2M | -44.2M | - |
Debt Issuance | 58.7M | 40.3M | 0 | 49.6M | 163.0M |
Debt Repayment | -116.5M | -51.7M | -53.6M | -77.0M | -96.5M |
Financing Cash Flow | -153.5M | -4.2M | -101.0M | -158.4M | -28.4M |
Free Cash Flow | 151.2M | -156.8M | 381.3M | 203.4M | 40.9M |
Net Change in Cash | -57.7M | -315.9M | 39.7M | 47.6M | -246.6M |
Cash Flow Trend
Vimta Labs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
39.84
Price to Book
7.45
Price to Sales
7.68
PEG Ratio
-2.19
Profitability Ratios
Profit Margin
19.93%
Operating Margin
24.42%
Return on Equity
17.78%
Return on Assets
14.43%
Financial Health
Current Ratio
2.92
Debt to Equity
2.25
Beta
-0.26
Per Share Data
EPS (TTM)
₹15.94
Book Value per Share
₹85.19
Revenue per Share
₹82.71
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
vimtalabs | 28.3B | 39.84 | 7.45 | 17.78% | 19.93% | 2.25 |
Syngene | 270.4B | 52.09 | 5.57 | 10.50% | 13.61% | 12.23 |
Dr. Lal PathLabs | 266.2B | 51.82 | 12.24 | 22.08% | 20.29% | 7.14 |
Krsnaa Diagnostics | 27.5B | 35.97 | 3.11 | 9.17% | 10.82% | 23.06 |
Suraksha Diagnostic | 15.5B | 49.87 | 7.35 | 15.91% | 12.43% | 42.28 |
Qualitek Labs | 3.0B | 42.80 | 3.10 | 12.27% | 8.97% | 37.74 |
Financial data is updated regularly. All figures are in the company's reporting currency.